Del(1p32): prime time in (ultra) high-risk myeloma

In this issue of Blood , Schavgoulidze et al validate the importance of the cytogenetic abnormality del(1p32) in risk stratification by analyzing a large cohort of patients with newly diagnosed multiple myeloma (NDMM). Importantly, the study also identifies an ultra high-risk group (UHR) with biallelic deletion, which demonstrates significantly adverse outcomes following current standard frontline treatment.1